
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is supported by highly compelling obefazimod data, with ABTECT-Maintenance showing clinical remission of 51.3% and 50.8% versus 10.4% placebo, plus strong endoscopic benefits and p<0.0001 significance, while longer-term follow-up showed durable efficacy through 144 weeks and no new safety signals over up to seven years of cumulative treatment. Its outlook is further strengthened by broad separation from placebo across advanced-therapy-naive and prior failure subgroups, including prior JAK inhibitor failures, suggesting the drug can address severe ulcerative colitis patients with meaningful unmet need and potential monotherapy utility. The company also appears financially and strategically well positioned, with about €1.2B cash providing runway into 4Q29, a clear commercialization plan targeting ~8,000 gastroenterologists, and a roadmap for Crohn’s data in mid-2027 and NDA submission by YE26.
Bears say
Abivax is viewed cautiously because obefazimod’s encouraging ulcerative colitis data still face a tougher commercial and clinical backdrop, with the next efficacy step increasingly expected to come from combination therapy rather than monotherapy. The company has no announced clinical combination program, while peers are already advancing dual-mechanism approaches and oral competition is intensifying, limiting obefazimod’s ability to break into the first advanced-therapy setting dominated by IL-23 and TL1A regimens. Although Abivax ended the quarter with €402.4MM in cash and €767.1MM of net proceeds, providing runway into 4Q29, the outlook remains pressured by revised commercial assumptions, capital-raise needs, and the view that approval in 4Q27 is already fully priced in.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Abivax SA (ABVX) Forecast
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares